VEGFA and hepatocellular carcinoma: HDACi may elicitpotent immunomodulatory activity through multiplemechanisms,28−31,39 and synergize with immunotherapy,one of the current standards of care for HCC.40,41 Since the glycosylated HDACi disclosed herein showed HCC cell-selectivity,antitumor immune-modulatory activities, and dual antibody blockadeof VEGF and PD-L1 pathways is less toxic than SORA alone, their combinationwith anti-PD1 therapy might be safe and highly effective.